Autoanticuerpos preformados en la pérdida precoz del trasplante renal

Abstract

Kidney transplant is the best therapeutic option for end stage renal disease (ERT); the knowledge of anti-human leukocyte antigen antibodies (HLA) in graft rejection along with the discovery of anti-calcineurinic immunosupressors, has allowed the decrease of early graft loss. Nonetheless, there are patients that still lose the graft rapidly, mainly due to thrombotic events. In the other hand, there have been reported antibodies against autologous antigens associated with graft rejection and loss mainly at long-term. However, the role of these autoantibodies is not known at short-term graft loss.Objectives: The main objective is to uncover the role of a series of pre-transplant autoantibodies and an endothelial damage biomarker in kidney graft loss during the first 6 and between 7 and 24 post-transplant months...